---
title: "GUANGXI LIUYAO GROUP released its 2024 annual performance, with a net profit attributable to the parent company of 855 million yuan, a year-on-year increase of 0.62%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/233249737.md"
description: "GUANGXI LIUYAO GROUP released its 2024 annual report, with operating revenue of 21.182 billion yuan, a year-on-year increase of 1.78%; net profit attributable to the parent company was 855 million yuan, a year-on-year increase of 0.62%. The net profit excluding non-recurring gains and losses was 837 million yuan, a year-on-year decrease of 0.01%. Basic earnings per share were 2.21 yuan, and it is proposed to distribute a cash dividend of 7.51 yuan for every 10 shares. The company continues to promote product research and development and market expansion in the pharmaceutical industry sector, maintaining steady growth"
datetime: "2025-03-26T08:50:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/233249737.md)
  - [en](https://longbridge.com/en/news/233249737.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/233249737.md)
generator: "portal-rs"
---

# GUANGXI LIUYAO GROUP released its 2024 annual performance, with a net profit attributable to the parent company of 855 million yuan, a year-on-year increase of 0.62%

According to the Zhitong Finance APP, Guangxi Liuyao Group (603368.SH) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 21.182 billion yuan, a year-on-year increase of 1.78%. The net profit attributable to shareholders of the listed company was 855 million yuan, a year-on-year increase of 0.62%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 837 million yuan, a year-on-year decrease of 0.01%. The basic earnings per share were 2.21 yuan. It is proposed to distribute a cash dividend of 7.51 yuan (including tax) for every 10 shares to all shareholders.

During the reporting period, the company adhered to the main line of "exploration and innovation" in the pharmaceutical industry sector, continuously promoting product research and development, quality control upgrades, and capacity enhancement. By leveraging commercial channel advantages and forming a professional marketing team, the company has steadily expanded its national market while consolidating its regional market, driving continued steady growth in the pharmaceutical industry sector

### Related Stocks

- [603368.CN](https://longbridge.com/en/quote/603368.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [RUBBER-Japan futures set for best week in five months on strong China demand](https://longbridge.com/en/news/296556839.md)
- [Vector Science files US provisional patent for orthopedic tissue-regeneration peptide platform](https://longbridge.com/en/news/296483037.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**